Bisantrene for Relapsed /Refractory AML

Summary

Induction of response in patients with AML that are either primary resistant (failed induction and or salvage therapy) or relapsed including post allogeneic stem cell transplantation and failed salvage therapy or cannot receive additional anthracycline .

Timeline

Start

2019-07-18

Primary completion

2020-05-19

Completion

2020-07-22

Drugs

Indications